ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics, Inc. (Nasdaq:ACOR) today announced that Chief Medical Officer (CMO) Enrique Carrazana, M.D. is leaving the Company effective January 4, 2016. Burkhard Blank, M.D., who has served as CMO for several biopharmaceutical companies including Boehringer Ingelheim, will assume the responsibilities of CMO on an interim basis. Dr. Carrazana is expected to serve as a consultant to the Company following his departure.
